5 May 2021 - - US-based biopharmaceutical company Affinivax, Inc has hired Elizabeth Radcliffe as chief financial officer, the company said.

She is a strategic business leader with experience managing finance and planning across the full range of biopharmaceutical R and D, commercial and business operations, including leadership roles at Arrakis Therapeutics, Agios Pharmaceuticals, and Biogen.

Radcliffe joins Affinivax as the company evolves its vaccine pipeline and expands its operations.

Elizabeth Radcliffe brings over 20 years of experience, with progressive financial leadership roles across the biopharmaceutical value chain at both large and small organizations, including contribution to six product launches.

She most recently served as vice president, finance and strategy and treasurer at Arrakis Therapeutics.

Prior to Arrakis, Radcliffe was vice president, financial planning and analysis at Agios Pharmaceuticals and spent over 10 years at Biogen, culminating in the role of senior director, head of R and D finance.

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine.

Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS platform technology, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases.

Affinivax was founded in 2014 with a seed investment from the Bill and Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children's Hospital.